Pharma News
02 Nov 2025 to 08 Nov 2025
Nov 8, 2025
Eli Lilly Secures a Historic Pricing Agreement with the U.S. for Its Multi-Billion Dollar Weight Loss Treatment...
Eli Lilly has reached an agreement with President Donald Trump to lower prices on its popular weight loss drugs, Mounjaro and Zepbound, in exchange for exemptions from import tariffs. This move comes as demand for these drugs surges, contributing to a 54% revenue increase for Lilly, which reported $10 billion from its weight loss portfolio.
Nov 8, 2025
AGTF apprehends individual suspected of trafficking drugs into the United States by hiding them in granite lamps.
The AGTF has arrested a man for allegedly smuggling drugs into the USA by hiding them in granite lamps. The operation highlights ongoing efforts to combat drug trafficking and ensure border security.
Nov 8, 2025
Ayush Department Takes Action Against Counterfeit Supplements in Gwalior Operation
The Ayush department in Madhya Pradesh raided Shivam Pharmacy in Gwalior, seizing counterfeit food supplements, including Advance Body Growth Powder. This operation highlights increasing concerns over spurious health products in the region.
Nov 8, 2025
India Intensifies Monitoring of Counterfeit Medications: CDSCO Implements Stringent Schedule M Regulations
India's drug regulatory authority, CDSCO, has intensified efforts against spurious and substandard medicines by enforcing strict Schedule M compliance. Additionally, the Jammu and Kashmir High Court has disposed of a related Public Interest Litigation, underscoring a nationwide commitment to pharmaceutical safety and quality.
Nov 8, 2025
Surge in Counterfeit Medications in India: Recent Incidents Showcase Nationwide Enforcement Efforts
India is intensifying its crackdown on spurious and substandard drugs amid growing quality concerns in the pharmaceutical sector. Recent incidents across multiple states have raised alarms, prompting regulatory actions. Government data indicates a significant rise in such cases between April 2024 and March 2025, highlighting the urgent need for improved drug safety measures.
Nov 8, 2025
Biotech Industry Surges: Encouraging Drug Trials Boost Investor Trust and Trigger Market Upswing
The biotech sector is experiencing a significant rally, driven by positive drug trial results from companies like UniQure, Praxis Precision Medicines, and Rapport Therapeutics. This resurgence is boosting investor confidence and market valuations, with firms like Vertex Pharmaceuticals and Merck also benefiting. The trend signals a transformative period for the pharmaceutical industry, emphasizing innovation and potential breakthroughs in treatment.
Nov 8, 2025
Researchers at IIT Madras create a cost-effective, minimally invasive device for glucose monitoring.
IIT Madras researchers have developed a patented, affordable, and minimally invasive glucose monitoring device aimed at improving diabetes management. This innovative device is designed to be user-friendly, enhancing accessibility for patients.
Nov 8, 2025
CDSCO Mandates Rigorous Implementation of Updated Schedule M in Response to Drug Quality Issues
The Central Drugs Standard Control Organisation (CDSCO) has mandated state drug regulators in India to enforce the revised Schedule M guidelines strictly, aiming to enhance pharmaceutical manufacturing standards amid growing drug quality concerns.
Nov 7, 2025
Trump Administration Finalizes Agreement on GLP-1 Medications, Medicare to Begin Coverage for Weight Loss Treatments...
The Trump administration has reached a deal with Eli Lilly and Novo Nordisk to reduce prices on their GLP-1 drugs in return for Medicare and Medicaid coverage. An Eli Lilly spokesperson confirmed that Medicare will provide coverage for weight-loss indications through an upcoming CMS pilot program.
Nov 7, 2025
Novo Nordisk stock declines following Trump's agreement to reduce prices of obesity medications - TradingView
Shares of Novo Nordisk and Eli Lilly fell after both companies agreed to lower prices for their GLP-1 weight-loss drugs, Wegovy and Zepbound, to between $149 and $350 for U.S. government programs. The price cuts may negatively impact short-term sales but are expected to boost volumes in the long run. Novo anticipates FDA approval for its new obesity pill by 2025, while Lilly expects approval for orforglipron by March.
Nov 7, 2025
NPPA sets retail prices for 28 medications and establishes ceiling prices for six formulations, according to DrugsControl Media Services.
The National Pharmaceutical Pricing Authority (NPPA) has set retail prices for 28 drugs and established ceiling prices for six formulations, as part of its efforts to regulate pharmaceutical pricing and ensure affordability, according to notifications released on November 4, 2025.
Nov 7, 2025
Overseeing Intellectual Property Rights in Indian Pharma Firms - Lexology
The Indian pharmaceutical sector emphasizes the importance of intellectual property rights (IPR) protection to foster innovation and competitiveness. Key strategies include patent and trademark registration, safeguarding trade secrets, and utilizing flexible licensing models. Understanding compulsory licensing under the Patents Act, 1970, is crucial for balancing innovation with public health needs, ensuring companies can protect their innovations while addressing access to medicines.
Nov 7, 2025
Super Generics Market Projected to Reach USD 98.3 Billion by 2034, Fueled by Patent Expirations - openPR.com
The Global Super Generics Market is expected to grow from USD 45.2 billion in 2024 to USD 98.3 billion by 2034, driven by patent expiries and advancements in drug formulation technologies. Key players include Teva Pharmaceutical Industries, Sun Pharma, and Dr. Reddy's Laboratories. The market is projected to register a CAGR of 8.1% during the forecast period.
Nov 7, 2025
Trump reaches agreement to reduce prices of weight loss medications - NBC Connecticut
President Trump announced an agreement with drugmakers Novo Nordisk and Eli Lilly to lower costs for GLP-1 weight loss drugs, Wegovy and Zepbound. Monthly out-of-pocket costs may range from $50 to $350, significantly reducing the current list prices over $1,000. The deal aims to improve access for millions, although coverage specifics for Medicare patients remain unclear.
Nov 7, 2025
US Update: Trump suggests potential trip to India, significant agreement on drug pricing, and Tesla's crucial voting event.
President Trump announced a significant drug pricing deal with Eli Lilly and Novo Nordisk, reducing costs for GLP-1 medications like Zepbound and Wegovy from over $1,300 to as low as $149. The agreement expands Medicare coverage for obesity treatments, marking a potential shift in the $100 billion obesity drug market.
Nov 7, 2025
Eli Lilly's weight loss medication Mounjaro ranks as the highest-grossing drug in India for October.
Eli Lilly's Mounjaro has emerged as India's top-selling drug by value in October, generating sales of 1 billion rupees ($11.38 million), according to Pharmarack. The anti-obesity drug, launched in March, has seen demand surge, with consumption in India being 10 times higher than Novo Nordisk's Wegovy, which launched in June. Total revenue for Mounjaro reached 3.33 billion rupees by the end of October.
Nov 7, 2025
Lilly and Novo Strike Agreement with White House to Lower Prices of Obesity Medications - AASTOCKS.com
US President Donald Trump announced an agreement with Eli Lilly and Novo Nordisk to significantly reduce prices of GLP-1 weight-loss drugs for Medicare and Medicaid beneficiaries starting in 2026. Discounts will be available to consumers through a new website, TrumpRx.gov, set to launch in January 2026.
Nov 7, 2025
Participant in Intellia trial with liver injury passes away - STAT News
The FDA has issued a second round of "Commissioner’s National Priority Vouchers," expediting reviews for drugs aligned with U.S. priorities, linked to deals with Eli Lilly and Novo Nordisk to reduce prices on popular weight loss medications. Additionally, Mark Cuban has launched a biosimilar deal, and a patient death has been reported in Intellia's CRISPR trial.
Nov 7, 2025
Eli Lilly Outperformed Novo in the Competition for Obesity Medications—Trump Now Mandates Price Reductions - Benzinga
President Trump announced a deal with Eli Lilly and Co. and Novo Nordisk to reduce prices for weight-loss drugs like Zepbound and Wegovy, making them more accessible to Americans. Starting April 2026, Medicare and Medicaid will cover these medications, lowering out-of-pocket costs significantly. Eli Lilly's CEO highlighted the deal as a turning point in obesity treatment, while Novo Nordisk emphasized the importance of access to medicine.
Nov 7, 2025
The impact of weight-loss injections: lucrative opportunities in the biotech sector - The Times
Biotechnology funds are thriving, with the S&P Biotechnology Select Industry Index rising 15% in October, outpacing the FTSE 100's 2.9% increase. A significant "patent cliff" is prompting big pharma to acquire smaller biotech firms to replenish their drug pipelines. Successful innovations, including weight-loss jabs and new cancer therapies, are driving investor interest and potential growth in the sector.
Nov 7, 2025
Shares of Novo Nordisk and Lilly decline following US drug pricing agreement - TradingView
Shares of Novo Nordisk and Eli Lilly fell after both companies agreed to lower prices for their GLP-1 weight-loss drugs, Wegovy and Zepbound, to between $149 and $350 for U.S. government programs. The deal aims to boost long-term sales volume despite a short-term impact on revenue. Novo anticipates FDA approval for its new obesity pill by 2025, while Lilly expects approval for orforglipron by March.
Nov 7, 2025
Trump negotiates with Lilly and Novo Nordisk to expand access to obesity medications - CNBC
President Donald Trump announced landmark agreements with Eli Lilly and Novo Nordisk to expand access to obesity drugs, including Eli Lilly's Zepbound and Novo Nordisk's Wegovy. Starting mid-2026, Medicare will cover GLP-1s for certain patients, potentially adding 40 million eligible users. The deals aim to lower costs and improve access, though legislative changes are needed for full implementation.
Nov 7, 2025
FDA broadens the National Priority Voucher initiative to include oral GLP-1 medications - TechTarget
The FDA has announced the second wave of National Priority Voucher recipients, including Eli Lilly's oral obesity drug Orforglipron and Novo Nordisk's oral Wegovy. This initiative aims to expedite drug reviews and enhance medication affordability. Other recipients include Vertex's Casgevy and GSK's dostarlimab. The program reduces review times from 10-12 months to 1-2 months.
Nov 7, 2025
Trump's agreement on a weight loss medication offers significant savings, though certain aspects remain unclear.
President Trump announced a plan to reduce prices for weight loss drugs Wegovy and Zepbound, aiming to make them more affordable for Americans. However, experts warn of significant gaps, including unapproved drugs and limited Medicare coverage. The deal promises starting doses at $149 monthly, but higher doses may cost more, leaving many patients still priced out.
Nov 7, 2025
The Defense of Regulatory Compliance Regarding "Inappropriate" Listings in the Orange Book - WilmerHale
Mark Ford and Kristen Parnigoni have contributed a chapter in the American Bar Association's Landslide Magazine discussing the implications of shifting the burden of proof in antitrust cases involving pharmaceutical patent holders. They analyze the regulatory compliance defense in Orange Book antitrust cases, referencing the FDA's Orange Book and the Hatch-Waxman Act's impact on generic drug approvals.
Nov 7, 2025
RFK Jr. Praises New Agreement on Anti-Obesity Medication - NTD News
The Trump administration has announced that select anti-obesity drugs will be available for as low as $149 per month, expanding access for more Medicare enrollees. This initiative aims to improve affordability and accessibility of these medications.
Nov 6, 2025
Novo Nordisk's CFO discusses the key solution for expiring GLP-1 patents | Fortune
Novo Nordisk faces challenges as patents for its successful GLP-1 drugs, Ozempic and Wegovy, are set to expire soon, prompting competition from Eli Lilly's Mounjaro. Despite a projected sales growth of 8-11% for 2025, the company's shares have dropped over 50% this year. Legal issues, including an anti-competition lawsuit from Pfizer, add to the pressure on Novo Nordisk.
Nov 6, 2025
Factory producing Alprazolam raided in Valsad, ₹22 crore worth of drugs confiscated; four individuals arrested.
The Directorate of Revenue Intelligence (DRI) has dismantled an illegal alprazolam manufacturing facility in Valsad, Gujarat, seizing drugs valued at ₹22 crores. Four individuals were arrested in connection with the operation, marking a significant crackdown on synthetic drug production in the region.
Nov 6, 2025
New Mechanism of Action for Second Medical Use: A Novel Approach (Video) - Patent - Mondaq
HGF Limited discusses a newly discovered mode of action for known compounds that can support patentable second medical use claims in Europe. The article highlights how European case law permits further protection for known substances upon identifying a new technical effect. It emphasizes the importance of seeking specialist advice for specific circumstances.
Nov 6, 2025
Current Trends: ADCs - Developments, Offerings, and Growth in CDMO - Insights from the DCAT Value Chain
Antibody drug conjugates (ADCs) are emerging as a significant segment in the bio/pharmaceutical industry, with growth prospects in pipelines and the CDMO sector. Gaurav Chaudhary, CEO of Roots Analysis, shares insights on market trends and the potential impact of evolving trade policies on global supply lines. The discussion is featured in the DCAT Value Chain Insights podcast.
Nov 6, 2025
Trump reaches agreement to reduce prices of Wegovy and Zepbound weight loss medications - NBC News
President Trump announced a deal to lower costs for GLP-1 weight loss drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, potentially reducing monthly out-of-pocket expenses to $50-$350. The agreement aims to expand access, particularly for Medicare and Medicaid patients, though details remain unclear. The administration expects direct-to-consumer pricing on TrumpRx by year-end.
Nov 6, 2025
Medicare Will Provide Coverage for Popular Obesity Medications - MedPage Today
Medicare will now cover semaglutide (Wegovy) and tirzepatide (Zepbound) for weight management in obese patients, as announced by President Trump. Starting next year, Medicare will pay $245 for these drugs, with eligible patients facing a $50 copay. The new pricing initiative aims to improve access and health outcomes for millions of Americans struggling with obesity.
Nov 6, 2025
Lilly and Novo to Reduce Prices of Obesity Medications in Agreement with Trump - Yahoo Finance
Eli Lilly & Co. and Novo Nordisk A/S have reached agreements with the Trump administration to reduce prices for their weight-loss drugs, Zepbound and Wegovy, in exchange for tariff relief and expanded Medicare access. Starting next year, eligible patients can access these medications for $50 a month, significantly lower than their current prices exceeding $1,000.
Nov 6, 2025
Trump reaches agreement to reduce prices of weight loss medications - NBC News
President Trump announced a deal to lower costs for GLP-1 weight loss drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, potentially reducing monthly out-of-pocket expenses to $50-$350. The agreement aims to expand access, particularly for Medicare and Medicaid patients, though details remain unclear. The administration expects direct-to-consumer pricing on TrumpRx by year-end.
Nov 6, 2025
Trump finalizes agreements with Lilly and Novo to reduce GLP-1 medication costs for Medicare - Modern Healthcare
Eli Lilly & Co. and Novo Nordisk A/S have reached agreements with the Trump administration to reduce prices for their popular weight-loss drugs. In return, the companies will receive tariff relief and expanded access for Medicare patients.
Nov 6, 2025
Some Obesity Medications Will Be Priced as Low as $149 Following Medicare's Expanded Coverage Under New Policy...
Medicare is set to expand coverage for certain obesity drugs, allowing costs to drop to as low as $149. This initiative is part of new deals announced by the White House, aimed at making obesity treatments more accessible to patients.
Nov 6, 2025
White House reaches agreement to reduce costs of obesity medications - NPR
The Trump administration has announced new deals with Novo Nordisk and Eli Lilly to provide obesity and Type 2 diabetes drugs, including Ozempic, Wegovy, Mounjaro, and Zepbound, to Medicare beneficiaries at $50 monthly copays. The initiative aims to lower drug prices and improve health outcomes, with the drugs available for $245 a month starting in April.
Nov 6, 2025
White House negotiates agreement to reduce costs of obesity medications | NCPR News
The Trump administration has announced new deals with Novo Nordisk and Eli Lilly to provide obesity and Type 2 diabetes drugs, including Ozempic, Wegovy, Mounjaro, and Zepbound, to Medicare beneficiaries for $50 monthly copays. The initiative aims to lower drug prices and improve health outcomes, with the drugs available for patients with specific health conditions starting in April.
Nov 6, 2025
Trump negotiates agreement with Eli Lilly and Novo Nordisk on obesity medication costs - CNBC
President Trump announced agreements with Eli Lilly and Novo Nordisk to significantly reduce prices for their weight loss drugs, Zepbound and Wegovy. Starting next year, monthly costs could range from $50 to $350, with Medicare covering obesity treatments for the first time in mid-2026. Eli Lilly will also lower prices on its direct-to-consumer platform, LillyDirect.
Nov 6, 2025
Liza Makowski from UT Health Science Center Heads Research on Extended Cancer Risk Factors...
Nov 6, 2025
UT Health Science Center Researcher Plays a Key Role in International Discussion on GLP-1 and Obesity
Nov 6, 2025
Braveheart Bio Secures $185 Million for a Medication That May Compete with a Bristol Myers Squibb Cardiovascular Treatment
Braveheart Bio is advancing its drug BHB-1893, an oral myosin inhibitor for obstructive hypertrophic cardiomyopathy (oHCM), into Phase 3 trials with $185 million funding. Unlike Bristol Myers Squibb's Camzyos, BHB-1893 shows potential for improved safety and efficacy. The drug aims to address unmet needs in oHCM treatment, with results indicating a wider safety margin and quicker therapeutic response.
Nov 6, 2025
India introduces its first homegrown CAR-T Cell Therapy, according to DrugsControl Media Services.
India has unveiled its first indigenous CAR-T Cell Therapy, a significant advancement in cancer treatment. This innovation was presented by the Prime Minister alongside other technological breakthroughs, including a quantum security chip and a quantum computing chip.
Nov 6, 2025
Latest Updates on Orange Book Legal Battles: The Impact of Patent Conflicts on Prescription Practices...
The FTC is intensifying efforts to combat improper patent listings by brand-name drug manufacturers that delay generic drug competition, which can keep prescription costs high. Recent actions include challenges to over 300 patents and support for cases like Teva Pharmaceuticals vs. Amneal. The ongoing litigation aims to enhance access to affordable medications and reduce healthcare costs.
Nov 5, 2025
Novartis invests in acquisitions to compensate for patent expirations - Chemistry World
Novartis has acquired Avidity Biosciences for $12 billion to enhance its neuroscience portfolio, particularly in rare diseases. This follows the loss of exclusivity for its heart drug Entresto. The deal aims to offset revenue losses from upcoming patent expiries. Novartis also recently acquired Tourmaline Bio and partnered with Arrowhead Pharmaceuticals for RNA therapies targeting neurodegenerative diseases.
Nov 5, 2025
Novo Nordisk Lowers Forecast Due to Decline in Drug Sales - Sharecafe
Novo Nordisk has revised its financial forecast for the fourth time this year, expecting revenue growth of up to 11% and operating profit of 7%, due to lagging sales of its drugs Wegovy and Ozempic. The company faces stiff competition from Eli Lilly & Co and is implementing aggressive measures, including layoffs and a $10 billion bid for Metsera, to regain market share.
Nov 5, 2025
Novo Nordisk Reports Mixed Results for Q3 and Lowers Growth Forecast - TradingView
Novo Nordisk (NVO) reported mixed Q3 results, with earnings per share down 26% to DKK 4.50, while revenue rose 5.2% to DKK 74.98 billion. Net profit fell 27% to DKK 20 billion. The company anticipates full-year sales growth of 811% at constant rates, despite challenges from currency fluctuations and weaker demand for its GLP-1 drugs, Ozempic and Wegovy.
Nov 5, 2025
Turning Point: The Influence of Overlooked Creatures on the Development of GLP-1 Medications - C&EN
In the latest episode of C&EN's podcast "Inflection Point," hosts David Anderson and Gina Vitale explore the historical roots of GLP-1 drugs like Ozempic and Wegovy. They discuss the evolution of diabetes treatment, including the discovery of GLP-1 and its implications for weight management, alongside insights from reporter Aayushi Pratap on the future of small-molecule GLP-1 drugs.
Nov 5, 2025
Strong sales of blockbuster medications drive Big Pharma's earnings for the third quarter as concerns over tariffs diminish.
Novo Nordisk and Pfizer are engaged in a competitive bid for obesity biotech Metsera, with Novo's offer reaching up to $10 billion. Eli Lilly's tirzepatide, sold as Mounjaro and Zepbound, dominated the GLP-1 market, while Novo's semaglutide sales lagged. Pfizer's CEO accused Novo of attempting to stifle competition. Overall, major drugmakers reported strong earnings amid fading tariff concerns.
Nov 5, 2025
This Firm Holds the Top Drug Globally. Is It Worth Investing $1000?
Eli Lilly's GLP-1 drug, tirzepatide, marketed as Mounjaro and Zepbound, became the world's best-selling drug in Q3, generating $10.1 billion in sales. Year-to-date sales reached $24.8 billion, surpassing Merck's Keytruda. Lilly's overall revenue rose 54% to $17.6 billion, with net income exceeding $6.1 billion. The company plans to expand access to Zepbound through a partnership with Walmart.
Nov 5, 2025
Novo Nordisk adjusts its forecast as it faces increased competition from Eli Lilly in the obesity medication market.
Novo Nordisk has lowered its full-year forecasts as sales growth for its obesity drug Wegovy slows, raising concerns about competition from Eli Lilly's Zepbound and copycat drugs. CEO Mike Doustdar is implementing a turnaround plan amid challenges, including pricing pressures and patent expirations. Novo is also in a $10 billion bid for biotech Metsera to enhance its drug pipeline.
Nov 5, 2025
Liza Makowski, PhD, from UT Health Science Center, Plays a Key Role in International Discussion on GLP...
A commentary co-authored by Dr. Liza Makowski discusses the long-term cancer risks associated with GLP-1 drugs like Ozempic, Wegovy, and Zepbound, which have revolutionized obesity treatment. Published in Nature Reviews Cancer, the article emphasizes the need for further research on these medications' effects on metabolic health and cancer risk, urging a combination of medication with lifestyle changes for optimal outcomes.
Nov 5, 2025
Amgen Sees Revenue Increase While Anticipating Phase III Results for Upcoming Major Product
Amgen's stock surged over 6% in after-hours trading on November 4 following the release of its Q3 earnings report.
Nov 5, 2025
Bahrain to boost its biotechnology industry through partnership with SandboxAQ | Semafor
Bahrain plans to invest $1 billion in biotech assets over three years, partnering with US firm SandboxAQ to utilize AI and quantum techniques for drug discovery. The initiative, licensed by Bahrain's sovereign wealth fund Mumtalakat, aims to accelerate drug development and diversify the economy beyond oil. SandboxAQ's software simulates biological processes, potentially democratizing biotech innovation globally.
Nov 5, 2025
Novo Nordisk reduces its annual profit forecast during the first quarter under the new CEO.
Novo Nordisk has lowered its full-year profit forecast for 2025, now expecting a growth of 4% to 7%, down from 10% to 16%. The adjustment follows slowing sales growth of its obesity drug Wegovy amid increased competition from Eli Lilly. Third-quarter sales rose 5% to 75 billion Danish crowns, below analyst expectations.
Nov 5, 2025
Following Colorado's implementation of a price cap on its medication, Amgen has once again filed a lawsuit against the state board responsible for the decision.
Amgen has filed a lawsuit against Colorado over a price cap of $600 for its rheumatoid arthritis drug Enbrel, imposed by the Colorado Prescription Drug Affordability Review Board. The company claims the cap is unconstitutional and will cause financial harm. This follows a previous lawsuit dismissed in April. The case is now assigned to Judge Daniel D. Domenico.
Nov 5, 2025
Genprex Obtains European Patent for Reqorsa® Treatment - The Globe and Mail
Genprex (GNPX) announced that the European Patent Office plans to grant a patent for its Reqorsa® Gene Therapy, which is designed to be used in combination with PD-1 antibodies for cancer treatment. This patent could enhance existing cancer therapies, particularly for lung cancer, and builds on existing patents in multiple countries.
Nov 5, 2025
Research Connects Frequent Heartburn and Hypertension Medications to Worse Breast Cancer Results
An international study involving 23,000 breast cancer patients has found that common medications for heartburn and high blood pressure may lead to poorer treatment outcomes. Conducted by researchers from the University of South Australia and Flinders University, the study emphasizes the need to consider drug interactions in breast cancer treatment planning.
Nov 5, 2025
Editorial | Wealthy Individuals Embrace Fitness, While the Less Fortunate Receive 'Advice' - The Ozempic Dilemma in India - NDTV
India faces a metabolic crisis with nearly 90 million adults living with diabetes. Novo Nordisk's Ozempic (semaglutide) has been approved for type-2 diabetes treatment, promising better blood sugar control and weight loss. However, its high cost (₹10,000-₹20,000/month) raises accessibility concerns. The article advocates for market-driven solutions to improve affordability and ensure equitable access to essential medications.
Nov 5, 2025
Trump's agreement with Lilly and Novo regarding generic medications - STAT News
The Trump administration is nearing agreements with Eli Lilly and Novo Nordisk to reduce prices and expand access to their weight loss drugs, potentially selling them for $149 a month through TrumpRx. This deal may also include Medicare coverage for weight loss, marking a significant step in the push for lower drug prices, though its impact remains uncertain.
Nov 5, 2025
Antibody treatments demonstrate potential in combating bird flu and HIV - Nature
Researchers are advancing antibody therapies to combat infectious diseases, including H5N1 avian influenza and HIV. A team led by Runhong Zhou developed a dual-target antibody that neutralizes multiple H5N1 strains, enhancing efficacy. Additionally, Zhiwei Chen's research identifies conserved regions on SARS-CoV-2, potentially improving vaccine effectiveness against evolving variants. These findings were presented at the Pandemic Research Alliance International Symposium in Melbourne.
Nov 4, 2025
Pharmaceutical company sees stock surge following acquisition of 20-year patent for dual-release gastro-resistant tablet.
Akums Drugs & Pharmaceuticals Ltd has gained investor interest after securing a 20-year patent for its innovative Dual Release Proton Pump Inhibitor (PPI) tablet aimed at providing long-lasting relief for GERD patients. The patent, effective from November 19, 2022, utilizes unique "tablet-in-tablet" technology to enhance absorption and improve patient compliance.
Nov 4, 2025
Actimed Therapeutics awarded Japanese patent for innovative composition of matter related to S...
Actimed Therapeutics Ltd has received a new composition of matter patent for S-pindolol benzoate (ACM-001.1) from the Japan Patent Office, enhancing its global intellectual property portfolio. This patent offers broad protection for S-pindolol benzoate, supporting its clinical development for cancer cachexia and muscle-wasting disorders. CEO Robin Bhattacherjee emphasized the importance of this patent in strengthening their market position.
Nov 4, 2025
Genprex Obtains Notice of Intent to Grant Patent for REQORSA+PD-1 | GNPX Stock Update
Genprex, Inc. announced that the European Patent Office intends to grant a patent for its Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for cancer treatment. This patent strengthens Genprex's intellectual property portfolio, enhancing protection for Reqorsa, which is being developed for lung cancer therapies.
Nov 4, 2025
BioNxt Solutions Shares Experience a Rise in Intellectual Property Worth - Ad-hoc-news.de
BioNxt Solutions has received European patent protection for its innovative sublingual Cladribine thin-film preparation, targeting the lucrative Multiple Sclerosis market projected to grow from $7.95 billion to $13.56 billion by 2032. CEO Hugh Rogers highlights this as a strategic milestone, positioning the company for potential partnerships and further international patent applications, including in the U.S. and Canada.
Nov 4, 2025
Genprex Reveals Plans to File for European Patent for Reqorsa® Gene Therapy - TradingView
Genprex, Inc. announced on November 4, 2025, that the European Patent Office intends to grant a patent for Reqorsa® Gene Therapy. This development expands existing patents for the therapy in the U.S., Japan, and other countries, enhancing its intellectual property portfolio.
Nov 4, 2025
Could Eli Lilly Create Millionaires? - The Globe and Mail
Eli Lilly's GLP-1 drug portfolio, particularly its weight loss drugs, has significantly boosted its stock price, rising over 500% in five years. However, concerns about future competition and patent expirations pose risks. Analysts suggest that while Eli Lilly remains strong, its current stock valuation may reflect overly optimistic expectations, leading to potential downside risks for investors.
Nov 4, 2025
Akums Drugs awarded a 20-year patent for its "Dual Release Gastro-Resistant Composition.
Akums Drugs and Pharmaceuticals Limited has secured a 20-year patent for its innovative "Dual Release Gastro-Resistant Composition," a next-generation Proton Pump Inhibitor (PPI) tablet aimed at treating moderate to severe gastroesophageal reflux disease (GERD). This formulation, utilizing unique tablet-in-tablet technology, offers extended relief and improved patient compliance, enhancing quality of life for GERD sufferers.
Nov 4, 2025
$20 Billion Market Potential for Breast Cancer Antibody Drug Conjugates (ADCs) and Patent Developments...
A new report from ResearchAndMarkets.com forecasts the breast cancer antibody drug conjugates (ADCs) market to exceed $20 billion by 2030, with sales expected to triple from over $7 billion in 2024. Key players include Daiichi Sankyo and AstraZeneca with Enhertu, while emerging companies like RemeGen and Zydus Cadila expand their reach. The report highlights ongoing clinical trials and innovative technologies shaping the future of breast cancer treatment.
Nov 4, 2025
Market Potential, Patents, Pricing, and Clinical Trials for Antibody Drug Conjugates in Lung Cancer
A new report from ResearchAndMarkets.com analyzes the lung cancer antibody drug conjugates market, highlighting clinical trials, innovative technologies, and key players like AstraZeneca, Daiichi Sankyo, and Pfizer. It emphasizes the potential of antibody drug conjugates, such as Ifinatamab Deruxtecan and Patritumab Deruxtecan, in improving treatment outcomes for lung cancer patients, particularly in advanced stages.
Nov 4, 2025
India Simplifies Rules by Allowing Self-Certification for More Than 1000 Low-Risk Medical Devices
India's government has introduced a self-certification process for over 1,000 low-risk medical devices, easing regulations and eliminating the need for mandatory licensing. This initiative aims to support the growth of the medical devices sector, as announced by the Central Drugs Standard Control Organisation (CDSCO).
Nov 4, 2025
Ways MRK, ABBV, and BMY Might Support Investor Portfolios During a Market Decline - TipRanks.com
The pharmaceutical sector is gaining momentum, with Merck (MRK), AbbVie (ABBV), and Bristol-Myers Squibb (BMY) identified as strong investment opportunities. Merck's KEYTRUDA faces patent expiration in 2028, while AbbVie contends with declining Humira sales. BMY, despite recent underperformance, offers a robust 5.4% dividend yield and potential growth through acquisitions. Each company presents attractive valuations for investors.
Nov 4, 2025
Collaborative Statement to USTR Regarding Pharmaceutical Costs and Medicine Accessibility in USMCA - Public Citizen
A coalition of organizations has urged the U.S., Mexico, and Canada to revise the USMCA to eliminate provisions that hinder access to affordable medicines. They advocate for the removal of the intellectual property chapter, citing issues like patent term extensions and market exclusivity that delay generic drug entry and increase healthcare costs.
Nov 4, 2025
Rise in Prescriptions for Psychotropic Medications Noted in Norway Amid COVID-19 Crisis
A study in Norway revealed a significant increase in psychotropic drug prescriptions during the COVID-19 pandemic, particularly for anxiety, depression, and sleep disorders. Researchers linked this rise to the pandemic's psychological effects, including isolation and economic instability, highlighting the need for monitoring mental health treatment trends during global crises.
Nov 4, 2025
Pfizer Increases Profit Forecast for 2025 as Novo Nordisk Increases Metsera Offer to $10 Billion
Pfizer raised its profit guidance for 2025 after reporting better-than-expected financial results, despite declining sales. This comes as Novo Nordisk increased its bid for Metsera to $10 billion, amid significant moves by Merck and Eli Lilly in the competitive pharmaceutical landscape. The industry is witnessing strategic investments and regulatory negotiations, particularly concerning obesity drug pricing.
Nov 4, 2025
Eli Lilly Experiences Significant Growth Due to Successful Drug Sales - Ad-hoc-news.de
Eli Lilly and Company reported a remarkable 54% revenue growth, driven by its diabetes and obesity medications, Mounjaro and Zepbound, generating over $10 billion in Q3. The company raised its annual revenue forecast to $63.0-$63.5 billion. Additionally, Eli Lilly is investing $3 billion in a new manufacturing facility in the Netherlands for Orforglipron, an experimental weight management drug.
Nov 4, 2025
Workers Excluded from Trump's Revival of Drug Manufacturing - The New York Times
Despite President Trump's push for U.S. drug manufacturing, the focus on building new factories largely overlooks generic medicines, which comprise 90% of prescriptions. The closure of a Shreveport plant, previously owned by Dr. Reddy’s Laboratories, highlights the decline in generic drug production, as it struggled financially while most manufacturing remains in lower-cost India.
Nov 4, 2025
Lilly and Novo Nordisk are close to reaching an agreement with the White House regarding the pricing of obesity medications, according to reports from Endpoints News.
Eli Lilly (LLY) and Novo Nordisk (NOVO_B) are set to announce new drug pricing agreements with the White House, which will include their popular weight loss medications. This deal is expected to facilitate coverage of these products under Medicare, according to sources reported by Endpoints News.
Nov 4, 2025
Reasons Behind Merck's Decline This Week - The Globe and Mail
Merck's stock fell over 3% following disappointing third-quarter results, including a revenue miss for its blockbuster drug Keytruda, which generated $8.1 billion, below the $8.2 billion expected. The company also lowered its 2025 revenue guidance, now anticipating $64.5 billion to $65 billion. Keytruda's patents are set to expire in 2028, raising concerns about future revenue.
Nov 4, 2025
Akums Drugs and Pharmaceuticals Limited Receives Patent Approval - EquityBulls
Akums Drugs and Pharmaceuticals Limited has been granted a 20-year patent for its innovative "Dual Release Gastro-Resistant Composition," aimed at treating moderate to severe gastroesophageal reflux disease (GERD). The new Dual Release Proton Pump Inhibitor (PPI) tablet, utilizing unique tablet-in-tablet technology, offers extended relief and improved patient compliance. The formulation has received DCGI approval and enhances quality of life for GERD patients.
Nov 3, 2025
Delhi High Court's Decision in the Case of F. Hoffmann-La Roche Ag & Anr. vs. Natco Pharma
The Delhi High Court dismissed F. Hoffmann-La Roche AG's appeal against Natco Pharma Ltd regarding the patent for Risdiplam, an SMA treatment. The court found Roche's patent invalid due to obviousness, allowing Natco to launch a generic version at ₹15,900, significantly lower than Roche's price of ₹6 lakh, highlighting implications for pharmaceutical patent litigation in India.
Nov 3, 2025
Akums Drugs obtains a 20-year patent for its "Dual Release Gastro-Resistant Formulation.
Akums Drugs has secured a 20-year patent for its "Dual Release Gastro-Resistant Composition," a next-generation Proton Pump Inhibitor (PPI) tablet aimed at treating moderate to severe Gastroesophageal Reflux Disease (GERD). This innovative formulation, developed with unique tablet-in-tablet technology, offers extended absorption and improved effectiveness, addressing limitations of traditional PPIs like Pantoprazole and Esomeprazole.
Nov 3, 2025
Akums Drugs Obtains 20-Year Patent for New GERD Therapy
Akums Drugs & Pharma has secured a 20-year patent for its innovative dual release gastro-resistant tablet aimed at treating Gastroesophageal Reflux Disease (GERD). Utilizing unique tablet-in-tablet technology, the formulation offers extended absorption and once-daily dosing. Approved by the Drug Controller General of India, this breakthrough could significantly improve treatment outcomes for millions of GERD patients globally.
Nov 3, 2025
US Senator expresses concern about substandard drug imports from India and China, calls for stricter regulations...
US Senator Jim Banks has called for enhanced FDA inspections of pharmaceutical manufacturing facilities abroad, citing concerns over the quality of drugs imported from India and China. The senator's push aims to ensure better safety and efficacy of medications entering the US market.
Nov 3, 2025
Countrywide Increase in Anti-Drug Operations: More than 13,000 Containers of Prohibited Cough Syrup and Tablets Seized...
In a nationwide crackdown on narcotic abuse, Indian law enforcement seized over 13,000 bottles of banned cough syrups, pills, and injections across five states. The operation targeted substances including rexogesic and phensedyl, highlighting the government's intensified efforts to combat drug-related issues.
Nov 3, 2025
Leading Drug Regulator at FDA Steps Down During Investigation and Legal Action, DrugsControl ...
Dr. George Tidmarsh has resigned as the director of the FDA's Center for Drug Evaluation and Research (CDER) just two days after being placed on administrative leave amid a federal investigation and lawsuit. The situation raises concerns about leadership stability within the agency. Aurinia Pharmaceuticals and Kevin Tang are also mentioned in relation to the ongoing developments.
Nov 3, 2025
IPC establishes and launches quality benchmarks for 22 types of blood components.
The Indian Pharmacopoeia Commission (IPC) has introduced quality standards for 22 blood components to ensure safe blood transfusions in India. These new general requirements and monographs aim to enhance the safety and efficacy of blood products sourced from humans.
Nov 3, 2025
24 Companies Caught with Rs 20 Lakh in Inferior Levocetirizine Tablets
Rajasthan's Food Safety and Drug Control Commissionerate has seized substandard Levocetirizine Dihydrochloride tablets valued at Rs 20 lakh from 24 pharmaceutical firms. The operation highlights the state's crackdown on counterfeit drugs, with the affected product being Wincet-L (Batch No. YLT25023) from M/s YL Pharma, deemed Not of Standard Quality (NSQ).
Nov 3, 2025
Coface explains the reasons behind the high cost of medications in the United States - Opportimes
A Coface report reveals that U.S. drug prices are significantly higher than in other developed countries due to a lack of centralized negotiation, opaque pricing, and profit-driven strategies. Brand-name drugs like Keytruda and Eliquis dominate spending. President Trump’s revived Most Favored Nation policy aims to lower prices, but its legal future is uncertain, potentially impacting pharmaceutical revenues.
Nov 3, 2025
Chamber Calls on Trump to Redirect Attention to Drug Pricing Initiatives - IPWatchdog.com
The U.S. Chamber of Commerce's Global Innovation Policy Center is urging President Trump to reconsider his Executive Order on Most Favored Nation (MFN) pricing, citing a report by Vital Transformation predicting a loss of 1.98 to 2.2 million jobs in the biopharma sector. The GIPC warns that MFN could hinder innovation and reduce clinical trial activity by up to 75%.
Nov 3, 2025
Eli Lilly's Rapid Growth Driven by Successful Medications - Ad-hoc-news.de
Eli Lilly reported a remarkable quarterly performance, with revenue soaring 54% to $17.6 billion and earnings per share at $7.02, surpassing market expectations. This growth is largely attributed to the success of its GLP-1 agonists, Mounjaro and Zepbound, which are revolutionizing diabetes and obesity treatment, raising questions about the sustainability of this explosive growth.
Nov 3, 2025
Akums Secures Two-Decade Patent for Dual Release PPI, Ensuring Extended Relief for GERD Sufferers
Akums Drugs and Pharmaceuticals Limited has been granted a 20-year patent for its 'Dual Release Gastro-Resistant Composition,' aimed at treating gastroesophageal reflux disease (GERD). This innovative formulation, utilizing tablet-in-tablet technology, offers extended relief and improved compliance for patients. The patent, numbered 573119, was issued on October 31, 2025, reinforcing Akums' commitment to advanced gastroenterological therapies.
Nov 2, 2025
Daiichi Sankyo (TSE:4568) Reports Earnings Growth, Strengthening Positive Outlook on Stability...
Daiichi Sankyo reported a 32.7% annual earnings growth over five years, with an 11.8% rise recently. Forecasts predict a 14.05% annual earnings increase, despite a slight dip in profit margins to 14.1% due to rising R&D costs. The company heavily relies on its oncology drugs, ENHERTU and Datroway, posing revenue concentration risks amid competitive pressures.
Nov 2, 2025
The future of the weight loss medication industry: tablets, competitors, and insurance coverage - CNBC
Eli Lilly has overtaken Novo Nordisk in the GLP-1 weight loss and diabetes drug market, capturing 57% of the share with its drugs Zepbound and Mounjaro. Novo Nordisk faces challenges from compounded alternatives and has seen its stock drop nearly 40% this year. Both companies are expanding supply and exploring new oral treatments, as the market is projected to reach $100 billion by 2030.
Nov 2, 2025
USC Quantum Technology Forum Showcases the Promise of Quantum Computing in Drug Development
The University of Southern California (USC) is at the forefront of quantum computing, with bipartisan support leading to over $4 billion in research funding. The establishment of the IBM Quantum Innovation Center and USC's first academic quantum computer positions it to revolutionize drug discovery and development. This convergence of technology and political will marks a significant shift in the industry.
Nov 2, 2025
Eli Lilly's Stock Rises Significantly Due to Strong Sales of Major Drug
Eli Lilly reported a remarkable third-quarter revenue of $17.60 billion, a 54% increase, driven by strong sales of its diabetes drug Mounjaro and obesity treatment Zepbound. The company is expanding its Puerto Rico facility and has partnered with Walmart to enhance market access. Future growth may hinge on the potential of its experimental oral GLP-1 medication, Orforglipron.
Nov 2, 2025
Committee Questions DoP and NPPA Regarding Increasing Medication Costs, DrugsControl Media Services
A parliamentary panel in New Delhi has urged the government to enhance mechanisms for controlling rising drug prices, highlighting that many essential and life-saving medications have become unaffordable in India, despite the country being one of the lowest-cost producers globally.
